Floatz logo

Dc-Cik

Digestive System Neoplasms

Shenzhen Hornetcorn Bio-technology Company, LTDCell therapyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

44 Active assets in the Digestive System Neoplasms cohort.

Asset / SponsorPhaseRating
Capecitabine
China Medical University, China
Phase 3BB
Sorafenib
Sichuan Cancer Hospital and Research Institute
Phase 3BB
Irinotecan
Pfizer
Phase 3BB
FLUOROURACILUM
Janssen Research & Development, LLC
Phase 3BB
pf-08634404
Pfizer
Phase 3B

View all 50 →

Same molecule, other indications

Dc-Cik is also rated in:

Postoperative ComplicationsDormant
BB
Indicative ·
67 / 100
View asset →
Cytokine-induced Killer CellsDormant
BB
Indicative ·
67 / 100
View asset →
Multiple Drug UseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →